MPS acceptance metric flip clouds guidance; Unbound synergy timeline slips
Q1 revenue up 20.4%, EBITDA margin jumps to 34.3% — but two inconsistencies from prior calls raise credibility questions on the long-term story.
What's new
- Revenue ₹224 cr, up 20.4% YoY; EBITDA ₹77 cr, up 53%; margin 34.3% vs 27.0%.
- Research Solutions core revenue grew 26.3% excluding AJE; margin reached 45.1%.
- Education revenue up 42.2% to ₹73.4 cr; EBITDA margin 35.1% via Unbound and AI work.
- Corporate learning margin expanded to 25.3% from 16.9% after restructuring.
Themes from the call
Demand
Research and education segments drove strong volume growth; corporate learning remains below market but growing.
Margins
Operating leverage from AI productivity and AJE pruning boosted EBITDA margin nearly 7 points.
Capital allocation
Cash ₹138 cr vs ₹37.6 cr debt; DSO improved to 45 days; management sees internal cash for acquisitions up to ₹500 cr.
Guidance watch
- FY27 consolidated EBITDA floor of ₹300 cr, called a 'floor not ceiling'.
- FY28 revenue ₹1,500 cr and EBITDA ₹450 cr as a qualified estimate (Q&A).
- Full-year FY27 Rule of 50 hopeful but not promised per quarter.
- Unbound margins expected to rise from 18-20% to mid-to-late 20s, eventual Rule of 50.
Risk flags
- Acceptance metric inconsistency undermines reported AI effectiveness data.
- Unbound synergy timeline now vague after earlier clear integration road map.
- Corporate learning growth of 6.9% lags its 12-13% market; management won't quantify catch-up timing.
Key quotes
-
"We run MPS on one principle when it comes to AI: it should show up in our revenue, not on slides."
— Rahul Arora, Chairman and CEO -
"Our controlled work shows a manuscript acceptance rate of nearly 52% against an industry baseline near 32%."
— Rahul Arora, July 2026 call
The brief
MPS delivered its strongest first quarter, with revenue up 20.4% and EBITDA margin jumping to 34.3% — the result of operating leverage, AI productivity, and a deliberate shift toward higher-value outcomes. But the quarter came with two guidance inconsistencies that investors cannot ignore. In May, management said a controlled trial showed a 52% manuscript acceptance lift versus a 32% industry baseline. In July, they said the same 52% was the absolute acceptance rate. That is a material difference. Separately, the Unbound synergy timeline, previously described as having a clear integration road map and EBITDA uplift path, is now an early-stage cross-sell effort with no committed timeline. The underlying business is compounding well: Research Solutions core growth of 26%, Education revenue up 42% with margin above 35%, and Corporate Learning restructuring paying off. Management guided FY27 EBITDA to comfortably cross ₹300 cr and flagged FY28 ₹1,500 cr revenue and ₹450 cr EBITDA as a qualified target. But the credibility gap around two key metrics — AI effectiveness and a major acquisition — will need to be closed before the street can underwrite the long-term compounding thesis with confidence. MPS is doing the right operational work. The communication needs to match.
Strong operational quarter, but two guidance inconsistencies test narrative credibility. Close the gap.